CD274 and neoplasm: Furthermore, it has been observed in several Batf3-/- mouse models that activated DCs are required to promote the anti-tumor efficacy of immunostimulatory antibodies, such as anti-PD-1, anti-PD-L1, and anti-CD137, and deficiencies in DCs limit the efficacy (35, 38).